These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37901362)

  • 1. Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective.
    Wills A; Mitha A; Cheung WY
    J Pharm Pharm Sci; 2023; 26():11877. PubMed ID: 37901362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors Affecting Citizen Trust and Public Engagement Relating to the Generation and Use of Real-World Evidence in Healthcare.
    Horgan D; Borisch B; Cattaneo I; Caulfield M; Chiti A; Chomienne C; Cole A; Facey K; Hackshaw A; Hendolin M; Georges N; Kalra D; Tumienė B; von Meyenn M
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we use existing guidance to support the development of robust real-world evidence for health technology assessment/payer decision-making?
    Capkun G; Corry S; Dowling O; Asad Zadeh Vosta Kolaei F; Takyar S; Furtado C; Jónsson P; Kleinermans D; Lambert L; Schiel A; Facey K
    Int J Technol Assess Health Care; 2022 Nov; 38(1):e79. PubMed ID: 36321447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of real-world data and evidence for medical devices: a qualitative study of key informant interviews.
    Polisena J; Jayaraman G
    Int J Technol Assess Health Care; 2020 Dec; 36(6):579-584. PubMed ID: 33161916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and Content of a Taxonomy to Support the Use of Real-World Evidence by Health Technology Assessment Practitioners and Healthcare Decision Makers.
    Murphy LA; Akehurst R; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; Franklin M; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):20-31. PubMed ID: 36706951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status.
    Kohlmann T; Wang C; Lipinski J; Hadker N; Caffrey E; Epstein M; Sadasivan R; Gondek K
    J Neurosci Nurs; 2013 Jun; 45(3):E3-14. PubMed ID: 23636073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 17. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
    Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
    Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy.
    Maruszczyk K; Aiyegbusi OL; Torlinska B; Collis P; Keeley T; Calvert MJ
    J Patient Rep Outcomes; 2022 Jun; 6(1):57. PubMed ID: 35652983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Healthcare stakeholders' perceptions and experiences of factors affecting the implementation of critical care telemedicine (CCT): qualitative evidence synthesis.
    Xyrichis A; Iliopoulou K; Mackintosh NJ; Bench S; Terblanche M; Philippou J; Sandall J
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012876. PubMed ID: 33599282
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.